An Integrated Risk Reduction Intervention can reduce body mass index in individuals being treated for bipolar I disorder: results from a randomized trial

作者：Frank Ellen^*; Wallace Meredith L; Hall Martica; Hasler Brant; Levenson Jessica C; Janney Carol A; Soreca Isabella; Fleming Matthew C; Buttenfield Joan; Ritchey Fiona C; Kupfer David J

来源：Bipolar Disorders, 2015, 17(4): 424-437.

DOI：10.1111/bdi.12283

• bipolar disorder
• health risks
• weight management

ObjectivesWe conducted a randomized, controlled trial comparing the efficacy of an Integrated Risk Reduction Intervention (IRRI) to a control condition with the objective of improving mood stability and psychosocial functioning by reducing cardiometabolic risk factors in overweight/obese patients with bipolar I disorder.
MethodsA total of 122 patients were recruited from our outpatient services and randomly allocated to IRRI (n=61) or psychiatric care with medical monitoring (n=61). Individuals allocated to IRRI received psychiatric treatment and assessment, medical monitoring by a nurse, and a healthy lifestyle program from a lifestyle coach. Those allocated to the control condition received psychiatric treatment and assessment and referral, if indicated, for medical problems. A mixed-effects model was used to examine the impact of the interventions on body mass index (BMI). Exploratory moderator analyses were used to characterize those individuals likely to benefit from each treatment approach.
ResultsAnalyses were conducted on data for the IRRI (n=58) and control (n=56) participants with 1 study visit. IRRI was associated with a significantly greater rate of decrease in BMI (d=-0.51, 95% confidence interval: -0.91 to -0.14). Three variables (C-reactive protein, total cholesterol, and instability of total sleep time) contributed to a combined moderator of faster decrease in BMI with IRRI treatment.
ConclusionsOverweight/obese patients with bipolar disorder can make modest improvements in BMI, even when taking medications with known potential for weight gain. Our finding that a combination of three baseline variables provides a profile of patients likely to benefit from IRRI will need to be tested further to evaluate its utility in clinical practice.

• 出版日期2015-6